Thus, aberrantly enhanced EPAS1 expression is driven by genomic rearrangement in ALCL subsets and by ONECUT2, likely affecting both BPDCN and ALCL (Figure S3). This evidence concerns the gene EPAS1 and anaplastic large cell lymphoma.